Vistagen Therapeutics

Vistagen Therapeutics

Vistagen was founded in 1998 but materially reshaped its identity upon Singh's leadership, focusing exclusively on neuroscience. The firm does not manage outside capital; it is a publicly traded development-stage company that advances its own drug candidates through the FDA process, funded by periodic public equity offerings. The platform is built around pherines, a proprietary class of nasal chemosensory molecules designed to regulate neural circuits without systemic absorption or benzodiazepine-like side effects. Lead candidate fasedienol (PH94B) is in Phase 3 for social anxiety disorder, with earlier-stage programs targeting major depressive disorder and vasomotor symptoms. Development is entirely U.S.-based, with clinical trial sites concentrated in North America. The company reported a workforce of approximately 40 full-time employees per its 2024 10-K filing, with R&D activities outsourced to contract research organizations. No adjacent vehicles or philanthropic structures are reported. In May 2024, Vistagen announced positive topline results from a Phase 3 trial of fasedienol, sending its stock sharply higher and marking its most significant clinical milestone to date. Vistagen's structural difference from a traditional asset manager or family office is fundamental: it is a single-pipeline public biotech, which means its "allocation" is binary—every dollar raised goes into advancing its own drugs toward regulatory approval, offering no diversification across sectors or strategies. Succession risk and governance are tied entirely to the board and CEO, not to a family or founder liquidity event.